Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03438396 · FLOW

Participant flow

A Trial of Tisotumab Vedotin in Cervical Cancer · Source last updated 2023-07-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Participants received IV tisotumab vedotin 2.0 mg/kg Q3W until radiographic disease progression verified by the IRC, unacceptable AEs requiring drug discontinuation, withdrawal of consent, lost to follow up or death, whichever occurred first.
    id
    FG000
    title
    Tisotumab Vedotin
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        9
      type
      Reason Not Specified
    2. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Lost to Follow-up
    4. reasons
      1. group Id
        FG000
        num Subjects
        85
      type
      Death
    5. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Not treated
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        102
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        101
      type
      Treated
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        102
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
A 102 participants with Recurrent or Metastatic Cervical Cancer were enrolled in the study and out of which 101 participants received study treatment. These participants were assessed until the participant experienced IRC-verified disease progression, started new anti-cancer therapy, discontinued the trial, or died.
recruitment Details
This study was conducted in Europe and the US.
Complete source fields
groups
  1. description
    Participants received IV tisotumab vedotin 2.0 mg/kg Q3W until radiographic disease progression verified by the IRC, unacceptable AEs requiring drug discontinuation, withdrawal of consent, lost to follow up or death, whichever occurred first.
    id
    FG000
    title
    Tisotumab Vedotin
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        9
      type
      Reason Not Specified
    2. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Lost to Follow-up
    4. reasons
      1. group Id
        FG000
        num Subjects
        85
      type
      Death
    5. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Not treated
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        102
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        101
      type
      Treated
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        102
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
A 102 participants with Recurrent or Metastatic Cervical Cancer were enrolled in the study and out of which 101 participants received study treatment. These participants were assessed until the participant experienced IRC-verified disease progression, started new anti-cancer therapy, discontinued the trial, or died.
recruitment Details
This study was conducted in Europe and the US.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice